{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lambert+Eaton+Myasthenic+Syndrome", "query": { "condition": "Lambert Eaton Myasthenic Syndrome" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 23, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lambert+Eaton+Myasthenic+Syndrome&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T22:55:58.078Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03062631", "title": "Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Congenital Myasthenic Syndrome" ], "interventions": [ { "name": "3,4-Diaminopyridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ricardo Maselli", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "3 Months", "maximum_age": "75 Years", "sex": "ALL", "summary": "3 Months to 75 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2023-06-02", "last_synced_at": "2026-05-21T22:55:58.078Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03062631" }, { "nct_id": "NCT00716066", "title": "Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autoimmune Disease", "Neurologic Autoimmune Disease", "Autologous Transplant Autoimmune", "Multiple Sclerosis Transplant", "MS Stem Cell Transplant", "Multiple Sclerosis Stem Cell Transplant", "Stiff Person Syndrome", "HCT for Neurologic Autoimmune Disorders", "CIDP Transplant", "Myasthenia Gravis Transplant", "Autoimmune Nervous System Disorder", "Central Nervous System Vasculitis", "Cerebellar Degeneration", "Chronic Inflammatory Demyelinating Polyneuropathy", "Lambert Eaton Myasthenic Syndrome", "Myasthenia Gravis", "Neuromyelitis Optica", "Opsoclonus Myoclonus Syndrome", "Rasmussen Subacute Encephalitis" ], "interventions": [ { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Syngeneic Bone Marrow Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "71 Years", "sex": "ALL", "summary": "Up to 71 Years" }, "enrollment_count": 53, "start_date": "2008-06", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-05-21T22:55:58.078Z", "location_count": 3, "location_summary": "Denver, Colorado • Seattle, Washington", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00716066" }, { "nct_id": "NCT01377922", "title": "A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lambert Eaton Myasthenic Syndrome" ], "interventions": [ { "name": "Amifampridine Phosphate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Catalyst Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2011-06", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2018-01-04", "last_synced_at": "2026-05-21T22:55:58.078Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01377922" }, { "nct_id": "NCT02189720", "title": "Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Congenital Myasthenic Syndrome", "Lambert-Eaton Myasthenic Syndrome", "Nystagmus, Acquired" ], "interventions": [ { "name": "Amifampridine Phosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Catalyst Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-05-21T22:55:58.078Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02189720" }, { "nct_id": "NCT01203592", "title": "Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Congenital Myasthenic Syndrome" ], "interventions": [ { "name": "Albuterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 21, "start_date": "2010-09", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2016-01-01", "last_synced_at": "2026-05-21T22:55:58.078Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01203592" }, { "nct_id": "NCT07226726", "title": "Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Congenital Myasthenic Syndrome" ], "interventions": [ { "name": "AlloEx exosomes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "The Foundation for Orthopaedics and Regenerative Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-01-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-05-21T22:55:58.078Z", "location_count": 2, "location_summary": "Naples, Florida • Irving, Texas", "locations": [ { "city": "Naples", "state": "Florida" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226726" }, { "nct_id": "NCT01378546", "title": "Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Lambert Eaton Myasthenic Syndrome (LEMS)" ], "interventions": [ { "name": "3,4-diaminopyridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Louis H. Weimer, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2005-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-18", "last_synced_at": "2026-05-21T22:55:58.078Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01378546" }, { "nct_id": "NCT01403402", "title": "Congenital Muscle Disease Study of Patient and Family Reported Medical Information", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy)", "Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C))", "Alpha-Dystroglycanopathy (Fukuyama CMD)", "Alpha-Dystroglycanopathy (LGMDR09 FKRP Related (Formerly LGMD2I))", "Alpha-Dystroglycanopathy (LGMDR11 POMT1 Related (Formerly LGMD2K))", "Alpha-Dystroglycanopathy (LGMDR13 FKTN Related (Formerly LGMD2M))", "Alpha-Dystroglycanopathy (LGMDR14 POMT2 Related (Formerly LGMD2N))", "Alpha-Dystroglycanopathy (LGMDR15 POMGnT1 Related (Formerly LGMD2O))", "Alpha-Dystroglycanopathy (LGMDR19 GMPPB Related (Formerly LGMD2T))", "Alpha-Dystroglycanopathy (LGMDR20 ISPD Related (Formerly LGMD2U))", "Alpha-Dystroglycanopathy (LGMDR24 POMGnT2 Related)", "Alpha-Dystroglycanopathy (Muscle Eye Brain Disease (MEB))", "Alpha-Dystroglycanopathy (Walker Warburg Syndrome (WWS))", "Choline Kinase B Receptor - CHKB", "Collagen VI Related Disorders", "Collagen XII Related Disorders", "Congenital Muscular Dystrophy Not Otherwise Specified (Including Merosin Positive)", "Congenital Muscular Dystrophy With Cataracts and Intellectual Disability (MDCCAID)", "Congenital Muscular Dystrophy With Joint Hyperlaxity", "Congenital Muscular Dystrophy With Rigid Spine Related to ACTA1", "Emery-Dreifuss Muscular Dystrophy", "GOLGA2-related Congenital Muscle Dystrophy With Brain Involvement", "LMNA Related Disorders", "Merosin Deficient CMD (Full or Partial)", "Nesprin Related MD (SYNE1)", "SELENON Related Disorders (Previously Known as SEPN1)", "SELENON Related Myopathy (Aka SEPN1)", "Telethonin CMD", "Congenital Myasthenic Syndrome", "Limb-Girdle Muscular Dystrophy", "LGMDD01 - DNAJB6 (Formerly LGMD1D)", "LGMDD05 - Collagen VI Related Bethlem Myopathy (Dominant)", "LGMDR07 - Telethonin (TCAP) Related (Formerly LGMD2G)", "LGMDR08 - TRIM Related (Formerly LGMD2H)", "LGMDR09 - FKRP Related (Formerly LGMD2I)", "LGMDR10 - Titin (TTN) Related (Formerly LGMD2J)", "LGMDR11 - POMT1 Related (Formerly LGMD2K)", "LGMDR13 - Fukutin (FKTN) Related (Formerly LGMD2M)", "LGMDR14 - POMT2 Related (Formerly LGMD2N)", "LGMDR15 - POMGnT1 Related (Formerly LGMD2O)", "LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P)", "LGMDR17 - Plectin (PLEC) Related (Formerly LGMD2Q)", "LGMDR18 - TRAPPC11 Related (Formerly LGMD2S)", "LGMDR19 - GMPPB Related (Formerly LGMD2T)", "LGMDR20 - ISPD Related (Formerly LGMD2U)", "LGMDR22 - Collagen VI Related Bethlem Myopathy (Recessive)", "LGMDR23 - LAMA2 Related", "LGMDR24 - POMGnT2 Related" ], "interventions": [], "intervention_types": [], "sponsor": "Cure CMD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 4000, "start_date": "2009-09", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2021-08-09", "last_synced_at": "2026-05-21T22:55:58.078Z", "location_count": 1, "location_summary": "Lakewood, California", "locations": [ { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01403402" }, { "nct_id": "NCT02090725", "title": "Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Muscle Weakness" ], "interventions": [ { "name": "3-4 Diaminopyridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeffrey A. Cohen, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "45 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2004-02", "completion_date": "2018-11-28", "has_results": true, "last_update_posted_date": "2019-05-21", "last_synced_at": "2026-05-21T22:55:58.078Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02090725" }, { "nct_id": "NCT06436742", "title": "A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Congenital Myasthenic Syndrome", "CMS" ], "interventions": [ { "name": "ARGX-119", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2024-09-24", "completion_date": "2028-01-24", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-05-21T22:55:58.078Z", "location_count": 2, "location_summary": "Sacramento, California • Chicago, Illinois", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06436742" } ] }